Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2465]

Scientists uncover clues behind drug resistance in bowel cancer

Scientists uncover clues behind drug resistance in bowel cancer

Exercise during chemotherapy may help immune cells fight cancer – patients invited to join new trial

Exercise during chemotherapy may help immune cells fight cancer – patients invited to join new trial

ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study of antibody-drug conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study...

ASCO 2025: Pro-inflammatory diets associated with worse outcomes for stage III colon cancer

ASCO 2025: Pro-inflammatory diets associated with worse outcomes for stage III colon cancer

ASCO 2025: Atezolizumab chemo combo leads to improved survival in deficient mismatch repair colon cancer

ASCO 2025: Atezolizumab chemo combo leads to improved survival in deficient mismatch repair colon cancer

ASCO 2025: Exercise programme may lower risk of recurrence and death for some colon cancer survivors

ASCO 2025: Exercise programme may lower risk of recurrence and death for some colon cancer survivors

ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers

ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric...

ASCO 2025: Trastuzumab deruxtecan can help some people with advanced gastric cancers live about 3 months longer

ASCO 2025: Trastuzumab deruxtecan can help some people with advanced gastric cancers live about 3 months longer

ASCO 2025: GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for people with diabetes

ASCO 2025: GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for people with...

ASCO 2025: First-line treatment with dual-targeted therapies and chemotherapy doubles overall survival in patients with BRAF-mutated metastatic colorectal cancer

ASCO 2025: First-line treatment with dual-targeted therapies and chemotherapy doubles overall survival in patients...

More from ecancer